摘要
目的评价痰液标本中p16基因启动子区甲基化联合血清中细胞角蛋白19片段(cytokeratin 19 fragment,CYFRA 21-1)和癌抗原15-3(CA15-3)的检测对非小细胞肺癌(NSCLC)的诊断价值。方法用巢式甲基化特异性聚合酶链反应(MSP)检测100例NSCLC患者痰液p16基因启动子区甲基化联合化学发光法检测患者血清中CYFRA21-1和CA15-3的水平,评价3种肿瘤标志物联合检测对NSCLC的诊断价值。结果NSCLC患者痰液中p16基因启动子区甲基化阳性率为61.0%;NSCLC患者血清中CYFRA21-1和CA15-3的实验敏感度分别为58.0%和38.0%;联合检测可明显提高NSCLC的检出率,敏感度79.0%,明显高于各种肿瘤标志物单项检测。结论痰液标本中p16基因启动子区甲基化联合血清中CYFRA21-1和CA15-3的检测可明显提高NSCLC的检出率,为早期诊断NSCLC提供了依据。
Objective To evaluate the diagnostic value of promoter hypermethylation of p16 gene in sputum specimens and cytokeratin 19 fragment （CYFRA21-1） and CA15-3 antigen in sera for non-small cell lung cancer. Methods Nested methylation-specific polymerase chain reaction（nMSP）was performed for the detection of promoter hypermethylation of p16 gene in sputum from 100 non-small cell lung cancer patients. The contents of CYFRA21-1 and CA15-3 in sera were detected by the method of microparticl chemicluminescence immunoassay（ECIA）. Results The hypermethylation of p16 in promoter regions were detected in 61.0% sputum specimens from non-small cell lung cancer patients. The experimental sensitivity of CYFRA21-1 and CA15-3 was 58.0 % and 38.0 % respectively. The detectable rate was increased by these three kinds of combinative experiments, by which the experimental sensitivity was up to 79.0% ,higher than one test alone significantly. Conclusion Combinative detection of hypermethylation of p16 gene in promoter regions from sputum specimens and CYFRA21-1 and CA15-3 could increase the detectable rate and experimental sensitivity of NSCLC. They might provide valuable evidence for the screening early diagnosis of NSCLC.
出处
《临床荟萃》
CAS
北大核心
2008年第15期1067-1070,共4页
Clinical Focus
